Ravidasvir Hydrochloride

盐酸拉维达韦

Report date: 2022/05/16 10:20:17
NME

Base Information

Drug NameRavidasvir Hydrochloride
Drug Alias Name雷达司韦瑞维达韦拉维达韦新力莱Asclevir +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis CVirus Diseases
Global Approved IndicationsHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryMainland China
Original Approved Date2020/07/29
Country/TerritoryUnited StatesNew ZealandAustralia +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPresidio Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJointown Pharmaceutical Group Co LtdAscletis Biological Technology (Hangzhou) Co Ltd
Inactive CompaniesAscletis Pharma IncPharco Pharmaceuticals LtdPresidio Pharmaceuticals Inc
Active IndicationsHepatitis C, ChronicHepatitis CVirus Diseases
Inactive IndicationsN/A

Other Information

ATC CodeJ05AP
Related LinksWikipediaDrugBank